ReviewThe Lancet. Infectious diseases2015
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.
Review in The Lancet. Infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 531 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
531 citing papers in PubMed, 4 syntheses or guidelines pooled it, 988 citations in OpenAlex.
- Cryptosporidium infections in animals across Asia (2015-2025): a systematic review and meta-analysis of prevalence, host range, geographic distribution, and molecular epidemiology.Veterinary research · 2026Pooled it
- Pooled it
- Global prevalence ofParasitology · 2023Pooled it
- The global prevalence ofParasitology · 2022Pooled it
- Effect of Nitazoxanide and Probiotic Treatment on Bangladeshi Children with Cryptosporidiosis.The American journal of tropical medicine and hygiene · 2025Trial
- Examination of ELISA against PCR for assessing treatment efficacy against Cryptosporidium in a clinical trial context.PloS one · 2023Trial
- Article
- A One Health Molecular Investigation and Exploratory Epidemiological Analysis of Cryptosporidium spp. in A Shared Human-Animal Ecosystem.Veterinary medicine and science · 2026Article
- A rapid sporozoite viability assay identifies leads and targetable enzymatic activities against the zoonotic Cryptosporidium parvum.International journal for parasitology. Drugs and drug resistance · 2026Article
- Unravelling the synergistic potential of Olibanum extract and Bacillus clausii in combating intestinal cryptosporidiosis in immunosuppressed mice.PLoS neglected tropical diseases · 2026Article
- Structure-Activity Relationship Study of Anti-Cryptosporidium Benzoxaboroles Yields Enhanced Potency and Curative Efficacy.Journal of medicinal chemistry · 2026Article
- Structural Basis for the Immunological Paradox of a High-Affinity Yet Non-Immunogenic MHC-I Epitope fromBiology · 2026Article
- Antimalarial cytoskeletal targeting with broad apicomplexan activity.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Functional Characterization and Inhibition Analysis of a Glutathione Transferase fromPharmaceuticals (Basel, Switzerland) · 2026Article
- A comprehensive proteome and the first phosphoproteome reveal extensive phosphorylation of carbohydrate metabolism in Cryptosporidium parvum sporozoites.Parasites & vectors · 2026Article
- The consequences ofEClinicalMedicine · 2026Article
- Mapping Prevalence, Diagnostics, and Evidence Gaps of Cryptosporidium in Southeast Asia Across Human, Animal, and Environmental Domains: Protocol for a One Health Scoping Review.JMIR research protocols · 2026Article
- The human parasite, Toxoplasma gondii, is paralyzed without two components of the apical polar ring.PLoS pathogens · 2026Article
- Rodent-borne pathogens as economic and zoonotic health threat to livestock farming: a review.One health (Amsterdam, Netherlands) · 2026Review
- Genomic heterogeneity of NAD(P)H dehydrogenase predisposes Cryptosporidium to clofazimine resistance.Nature microbiology · 2026Article
471 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 16 institutions in 4 countries.
Funding
Abstract
Cryptosporidium spp are well recognised as causes of diarrhoeal disease during waterborne epidemics and in immunocompromised hosts. Studies have also drawn attention to an underestimated global burden and suggest major gaps in optimum diagnosis, treatment, and immunisation. Cryptosporidiosis is increasingly identified as an important cause of morbidity and mortality worldwide. Studies in low-resource settings and high-income countries have confirmed the importance of cryptosporidium as a cause of diarrhoea and childhood malnutrition. Diagnostic tests for cryptosporidium infection are suboptimum, necessitating specialised tests that are often insensitive. Antigen-detection and PCR improve sensitivity, and multiplexed antigen detection and molecular assays are underused. Therapy has some effect in healthy hosts and no proven efficacy in patients with AIDS. Use of cryptosporidium genomes has helped to identify promising therapeutic targets, and drugs are in development, but methods to assess the efficacy in vitro and in animals are not well standardised. Partial immunity after exposure suggests the potential for successful vaccines, and several are in development; however, surrogates of protection are not well defined. Improved methods for propagation and genetic manipulation of the organism would be significant advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.